Randox Laboratories Limited

Randox Teoranta

Other

Ciaran Richardson

Ivan Robert McConnell

John Victor Lamont

Peter Fitzgerald

Elouard Benchikh

Deepesh Upadhyay

Stephen Peter Fitzgerald

Ivan Robert Mcconnell

John Lamont

Konstantinos Makris

Kenneth Martin

Ivan Mcconnell

The disclosure describes the use of glial fibrillary acidic protein as a marker of pernicious stroke.

GFAP accumulating in stroke

The present invention describes methods of determining the glycosylation signature and determining the level of a protein in a sample obtained from a patient. The present invention also describes use of a patient protein glycosylation profile to identify the presence or absence of a disease in subjects.

Determination of glycosylation signature

A substrate comprising a coating of a masking material, and a plurality of discrete reaction zones onto which one or more binding agents are intended to be attached, wherein said zones are uncoated areas on the substrate.

Relating to substrates for the attachment of molecules

The disclosure provides methods and solid states devices for detecting and staging chronic kidney disease in a patient, where the levels of biomarkers in a sample obtained from a patient are elevated or reduced compared to the levels in a sample obtained from healthy subject. In addition, the disclosure provides the use of methods and solid state devices for measurement of specific biological markers for determining the efficacy of a treatment for chronic kidney disease and for determining a drug treatment protocol for a subject suffering from chronic kidney disease.

Kidney disease biomarker

Substrates for the attachment of molecules

Growing community of inventors

Donegal, Ireland

Ciaran Richardson